Minerva Neurosciences, Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $41.2M | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $11.9M | $12.7M | $14.6M | $32.0M | $22.0M | $58.1M | $34.9M | $30.3M |
| SG&A Expense | $9.9M | $10.4M | $10.6M | $13.3M | $17.3M | $17.7M | $16.8M | $10.9M |
| Operating Income | $-21.8M | $-23.1M | $-25.2M | $-45.4M | $1.8M | $-75.9M | $-51.7M | $-41.2M |
| Operating Margin | — | — | — | — | 4.5% | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | $-32.1M | $-51.7M | $1.9M | $-74.4M | $-50.2M | $-40.9M |
| Income Tax Expense | — | — | — | $-1.8M | — | $-2.3M | $0 | $-9.4M |
| Net Income | $1.4M | $-30.0M | $-32.1M | $-49.9M | $1.9M | $-72.2M | $-50.2M | $-31.5M |
| Net Margin | — | — | — | — | 4.7% | — | — | — |
| EPS (Basic) | $0.19 | $-4.61 | $-6.01 | $-9.35 | $0.05 | $-1.85 | $-1.29 | $-0.83 |
| EPS (Diluted) | $0.19 | $-4.61 | $-6.01 | $-9.35 | $0.05 | $-1.85 | $-1.29 | $-0.83 |
| Shares Outstanding (Basic) | 7.6M | 6.5M | 5.3M | 5.3M | 40.8M | 39.0M | 38.9M | 38.7M |
| Shares Outstanding (Diluted) | 7.6M | 6.5M | 5.3M | 5.3M | 40.9M | 39.0M | 38.9M | 38.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |